alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
"['H1106D', 'R1170Q', 'N1100S', 'M1250T', 'V1092I']","[{'ncitCode': 'C162676', 'drugName': 'Elzovantinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38564707'],[],"Elzovantinib, capmatinib and tepotinib are orally available, small molecule MET tyrosine kinase inhibitors. Promising laboratory data support the use of select MET tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC) harboring MET tyrosine kinase domain (TKD) mutations. In case reports from the Phase I/II (NCT03993873) trial of elzovantinib in MET-altered solid tumors, two patients with NSCLC harboring MET TKD mutations (MET H1094Y and MET F1200I) were treated with elzovantinib achieved partial responses (PMID: 38564707). Preclinical studies with Ba/F3 cells expressing MET N1100S, V1092I, H1106D, R1170Q and M1250T demonstrate sensitivity to elzovantinib, capmatinib and tepotinib as measured by sustained growth inhibition following treatments and decreased IC50 values compared to wildtype (PMID: 38564707)."
"['H1106D', 'R1170Q', 'N1100S', 'M1250T', 'V1092I']","[{'ncitCode': 'C90564', 'drugName': 'Capmatinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38564707'],[],"Elzovantinib, capmatinib and tepotinib are orally available, small molecule MET tyrosine kinase inhibitors. Promising laboratory data support the use of select MET tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC) harboring MET tyrosine kinase domain (TKD) mutations. In case reports from the Phase I/II (NCT03993873) trial of elzovantinib in MET-altered solid tumors, two patients with NSCLC harboring MET TKD mutations (MET H1094Y and MET F1200I) were treated with elzovantinib achieved partial responses (PMID: 38564707). Preclinical studies with Ba/F3 cells expressing MET N1100S, V1092I, H1106D, R1170Q and M1250T demonstrate sensitivity to elzovantinib, capmatinib and tepotinib as measured by sustained growth inhibition following treatments and decreased IC50 values compared to wildtype (PMID: 38564707)."
"['H1106D', 'R1170Q', 'N1100S', 'M1250T', 'V1092I']","[{'ncitCode': 'C88314', 'drugName': 'Tepotinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38564707'],[],"Elzovantinib, capmatinib and tepotinib are orally available, small molecule MET tyrosine kinase inhibitors. Promising laboratory data support the use of select MET tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC) harboring MET tyrosine kinase domain (TKD) mutations. In case reports from the Phase I/II (NCT03993873) trial of elzovantinib in MET-altered solid tumors, two patients with NSCLC harboring MET TKD mutations (MET H1094Y and MET F1200I) were treated with elzovantinib achieved partial responses (PMID: 38564707). Preclinical studies with Ba/F3 cells expressing MET N1100S, V1092I, H1106D, R1170Q and M1250T demonstrate sensitivity to elzovantinib, capmatinib and tepotinib as measured by sustained growth inhibition following treatments and decreased IC50 values compared to wildtype (PMID: 38564707)."
